thuja presentation bio business summer school 2015
TRANSCRIPT
BioBusiness Summer School 2015
What is venture capital?
Venture• High risk enterprise• Technology based• Relatively lengthy development trajectory• Much money needed (millions of Euros)• No short-term profitability or positive cash flow
Capital• Financing in return for an equity stake (shares: co-ownership)
Sub-category of private equity• Investments in private (non-public) companies
2
BioBusiness Summer School 2015
Why venture capital
3
Life of company (years)
Capi
tal n
eed
(mio
Eur
o)
University Late stage VCs
Informal investors Revenues from sales and partnering
Subsidies, “soft loans”
Early stage VCs
Bank loans
BioBusiness Summer School 2015
Venture capital and innovative companies
• Venture capital is an essential part of the innovation ecosystem
• Particularly important to enable transition of technological inventions towards commercially viable products
• Almost all successful high-growth technology companies have had venture capital at their basis to fund product development
4
BioBusiness Summer School 2015
Types of VCs – by stage
Seed/early stage• Fund size € 10-50 mio• Limited geographical focus• Hands-on, active, assistance in setting up and building company and further fund
raising• Seed capital, series A-B funding
Mid/late stage• Fund size € 50-250 mio and beyond• Continental or even WW focus• Mature companies, experienced management• Supervision from a distance• Series B-E funding
6
BioBusiness Summer School 2015
How a VC makes money (ROI)
Trade sale • Sale of shares to an external buyer• Sale of part of, or entire, company in return for cash
Initial Public Offering (IPO)• Sale and trade of shares at a stock exchange (public trading)• In recent years the IPO route has not been an option
Dividends (profit share)• Do not provide the return on investment pursued, poorly compatible with pursued
financial dynamics
7
BioBusiness Summer School 2015
How a venture capital fund gets its money (2)
Party
Institutional investors (pension funds, insurance companies, banks)
Family officeshigh net worth individuals
Governments (RVO,European Investment Fund)
Universities
Companies
9
Drivers
Return
Return, impact investment, philantropy
Stimulate innovation climate
Stimulate spin-offs, return, “valorization”
Strategic motive
BioBusiness Summer School 2015
How a venture capital fund works
10
Venture capital fund
Portfolio
Valuecreation
Exit
Return
Institutional investors
BioBusiness Summer School 2015
The work of the VC
11
Venture capital fund
Portfolio
Value creation
Exit
Return
Institutional investors
Fundraising Selection
Active support
Active support
BioBusiness Summer School 2015
Venture capital - fund structure
Most funds have a similar set-up, typically:
• Closed end: fund ends after 10 years (+2)
• Fund investors (limited partners) commit money, and money is called pro rata for each investment/round
• Fund management co-invests in fund (1%) – and hence also benefits from a good fund performance
12
BioBusiness Summer School 2015
VC money is difficult to obtain
13
150+ new business plans
5-10 selected
1-2 new Investments
PER YEAR
BioBusiness Summer School 2015
The quest for return on investment
A VC fund is successful if it generates a good return on investment
• Quick exit generates better return than exit after long period (IRR)
• Overall fund money multiple of >3x (or better: IRR >30%)
• Per fund portfolio of 10-12 companies 3-4 companies need to be exited with multiple of 5-10x
How to select high-potential propositions with a prospective for good return on investment?
14
BioBusiness Summer School 2015
A VC weighs the following characteristics
Proposition• Fit to fund focus and strategy• Feasibility• Realistic plan, timelines, costs• Commercial potential• Risks
Team• Experience, capability and credibility• Chemistry, trust and added value between team – VC
ROI• Pre-money valuation: number of shares obtained for investment• Investment round size, use of proceeds, value creation• Exit possibilities, exit horizon, capital need toward horizon
16
BioBusiness Summer School 2015
What to watch for in a VC
Fund focusFit of VC with proposition, in terms of experience, portfolio, but also company stage
NetworkDoes the VC have an interesting and relevant network?
Know how and experienceAre fund managers of potential value to the company?
Chemistry Ability of building fruitful relationship during the long-term commitment
17
BioBusiness Summer School 2015
Investment process and support Thuja
18
Source
Clos
ingSelection Analysis
Active sourcing:• Universities• Network• Field monitoring• Meetings
Passive sourcing
• Focus funds• Investment
criteria
• Presentation(s)• SWOT• Business plan
refinement• Team• Preliminary
Investment Proposal
Negotiation
Term
she
et
Value creationDue diligence
• In-depth due diligence
• Structuring• Legal
documentation• Internal approval
process
• Terms• Valuation• Investment• Business plan• Structure• Capital need• Syndicate
Exit
• “Hands-on” support and guidance
• Leverage network• Supervisory
Board• Connect to VCs
and business partners
• Support business development
• Connect to exit parties
• Active exit management
Investment process Support
BioBusiness Summer School 2015
Thuja Capital
Management of five funds• AlpInvest Life Sciences portfolio (completed)• Thuja Capital Healthcare Fund I & II (divestment stage)• Thuja Capital Healthcare Seed Fund I & II (investment stage)
Team• Harrold van Barlingen – managing partner & founder• Michel Briejer – managing partner• Undisclosed – partner-to-be• Martin Solleveld – financial controller
Office: Utrecht Science Park
19
BioBusiness Summer School 2015
Thuja Capital Healthcare (Seed) Fund - portfolio
20
Company (location) Product Class Status
ArGEN-X (NL/B) TherapeuticsParticipation since 2008, IPO 2014
Bioceros (NL) Therapeutics Sold in 2011
Cavadis (NL) Medical devices (diagnostics) Participation since 2010
Cristal Therapeutics (NL) Therapeutics Participation since 2012
DCPrime (NL) Therapeutics Participation since 2010
Fabpulous (NL) Medical devices (diagnostics) Participation since 2009
Hemics (NL) Medical devices (diagnostics) Participation since 2011
Mellon Medical (NL) Medical devices Participation since 2013
NightBalance (NL) Medical devices Participation since 2011
Okapi Sciences (B) Therapeutics Sold in 2014
TheraSolve (B) Medical devices Participation since 2011
BioBusiness Summer School 2015
Thuja Capital Healthcare (Seed) Fund II
Geography• The Netherlands and Belgium (mainly Flanders)
Stage• Early stage: Seed, Series A
Technology focus: medical products• Novel therapeutics, new formulations, novel applications• Medical devices, medical technology, diagnostics, biomarkers• Cross-over products• Medical foods
21
BioBusiness Summer School 2015
Fundraising trends
Difficult fundraising climate (still)• Poor financial climate does not stimulate appetite and makes investors risk averse• Banks are faced with Basle-3, insurance companies with Solvency-2 rules which
reduces their ability to invest• Pension funds are rethinking their investment strategy
Upcoming importance of alternative money sources• European Investment Fund and national fund-of-funds• Family offices and private investors• Strategic investors
22
BioBusiness Summer School 2015
Contact information
23
This document neither contains an invitation or offering of securities, nor should it be regarded as an investment advice. This document may not be reproduced or (re)distributed in whole or in part in any form or by any means without the prior written consent of Thuja Capital. The information contained in this document , including the additional oral and written information has been compiled from sources Thuja Capital believes to be reliable. Thuja Capital will not assume nor accept any responsibility in relation thereto. This information may be changed or updated by Thuja Capital without notice.
Thuja CapitalYalelaan 403584 CM Utrecht
Tel: 030 253 3849Mobile: 06 2246 2927Email: [email protected]
Web: www.thujacapital.comTwitter: @ThujaCapital